Seer, Inc. (SEER)
NASDAQ (NGS) NASDAQ (NGS) Primary Summary
Seer, Inc. (SEER) Q3 2025 Earnings Call Transcript
Seer, Inc. ( SEER ) Q3 2025 Earnings Call November 6, 2025 4:30 PM EST Company Participants Kelly Gura Omid Farokhzad - Founder, CEO, & Chair of the Board of Directors David Horn - President,Treasurer & CFO Conference Call Participants William Ruby - TD Cowen, Research Division Presentation Operator Good day, and welcome to the Seer Third Quarter 2025 Earnings Conference Call. [Operator Instructions] Please note this event is being recorded.
Seer, Inc. (SEER) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)
Seer, Inc. (NASDAQ:SEER ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 12:20 PM EDT Company Participants Omid Farokhzad - Founder, CEO, & Chair of the Board of Directors Conference Call Participants Yuko Oku - Morgan Stanley, Research Division Presentation Yuko Oku Equity Analyst Hi. My name is Yuko Oku and I'm part of the life science tools and diagnostics team at Morgan Stanley.
Seer, Inc. (SEER) Q2 2025 Earnings Call Transcript
Seer, Inc. (NASDAQ:SEER ) Q2 2025 Earnings Conference Call August 6, 2025 4:30 PM ET Company Participants David R. Horn - President,Treasurer & CFO Kelly Gura - Corporate Participant Omid C.
Seer, Inc. (SEER) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
When is the next earnings date?
Has Seer, Inc. ever had a stock split?
Seer, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Omid C. Farokhzad CEO | NASDAQ (NGS) Exchange | 81578P106 CUSIP |
| US Country | 134 Employees | - Last Dividend | - Last Split | 4 Dec 2020 IPO Date |
Overview
Seer, Inc. is a pioneering life sciences company dedicated to enhancing our understanding of the proteome's complex biology. Proteomics, the study of proteins, is crucial for comprehending biological systems and disease mechanisms, offering vast potential for innovations in healthcare and disease treatment. Established in 2017 and headquartered in Redwood City, California, Seer, Inc. embarked on its mission to revolutionize proteomic analysis with advanced technological solutions. Initially known as Seer Biosciences, Inc., the company underwent a rebranding to Seer, Inc. in July 2018, marking a significant milestone in its journey. With operations spanning across China, Australia, Eastern Europe, Israel, and Japan, Seer, Inc. aims to make its innovative solutions accessible to a global audience. The company's target market includes academic institutions, life sciences, and research laboratories, along with biopharmaceutical and biotechnology companies. These entities utilize Seer's products for non-diagnostic and non-clinical research purposes, contributing to the expansion of knowledge within the scientific community.
Products and Services
- Proteograph Product Suite
At the core of Seer, Inc.'s offerings is the Proteograph Product Suite, an integrated array of products designed to elevate proteomic analysis to new heights. This suite encompasses proprietary engineered nanoparticles and consumables, complemented by automation instrumentation and sophisticated software. The Proteograph Product Suite stands out for its ability to perform comprehensive proteomic analyses, making it a vital tool for research laboratories globally. Its design caters to the needs of virtually any lab, ensuring seamless integration into existing research workflows. Primarily intended for research use only, this suite equips scientists and researchers with the means to delve deeper into the proteome, unveiling insights that were previously beyond reach. By democratizing access to high-quality proteomic data, Seer, Inc. facilitates groundbreaking discoveries in biology, medicine, and pharmacology.
